Table 1. Summary of immune checkpoint inhibitor experience in neuroendocrine tumors.

Patient Age	Diagnosis	Grade	Treatment	Prior Treatments	Duration of Treatment	Outcome
43	Stage IV pNET, Non functional	II	Pembrolizumab	somatostatin analog, sunitinib, capecitabine and temozolamide, everolimus and fosbretabulin	16 months	Progressed after 16 months of stable disease; Initially KPS increased from 60% to 90%; 20 pound weight gain and enjoyed a good quality of life for over a year until progression.
49	Stage IV NET of unknown primary, Non functional	II	Nivolumab	somatostatin analogs, everolimus, capecitabine and temozolomide	6 months	KPS increased from 70% to 90% initially. Progressed after 6 months on treatment
71	Stage IV pNET, Gastrin producing	I	Nivolumab	somatostatin analog, everolimus, capecitabine and temozolomide, fosbretabulin	6 months	Stable disease per imaging
75	Stage IV, Bronchial NET, Non functional	I	Pembrolizumab	Somatostatin analog, everolimus, XRT	3 months	Stable disease per imaging